Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies
BMS-986156 was well-tolerated with ipilimumab, nivolumab, with or without SABR. Outcomes were encouraging in this population, as more than half of patients had stable disease/partial response.
Authors
- Joe Y. Chang (ORCID: https://orcid.org/0000-0002-8435-2083)
- Daniel D. Karp (ORCID: https://orcid.org/0000-0002-5017-328X)
- Wei Li (ORCID: https://orcid.org/0000-0002-9692-9820)
- David S. Hong (ORCID: https://orcid.org/0000-0001-8721-1609)
- Jordi Rodón (ORCID: https://orcid.org/0000-0001-6467-3632)
- Nathan Comeaux (ORCID: https://orcid.org/0000-0002-1077-9607)
- Aileen B. Chen (ORCID: https://orcid.org/0000-0002-5385-3360)
- Girish S. Shroff (ORCID: https://orcid.org/0000-0001-9488-7439)
- Vivek Verma (ORCID: https://orcid.org/0000-0002-5863-6023)
- James W. Welsh (ORCID: https://orcid.org/0000-0002-2255-8502)
- Ecaterina E Ileana Dumbrava (ORCID: https://orcid.org/0000-0002-1959-0536)
- Xinyan Xu
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1136/jitc-2024-009975
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Bristol-Myers Squibb
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Cancer Institute